Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SER 109

Drug Profile

SER 109

Alternative Names: SER-109

Latest Information Update: 03 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seres Health
  • Developer Seres Therapeutics
  • Class Anti-infectives; Bacteria
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium difficile infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Clostridium difficile infections

Most Recent Events

  • 31 Mar 2020 Seres Therapeutics plans to engage in discussion with US FDA regarding a filing for product approval in Clostridium difficile infections (Recurrent)
  • 31 Mar 2020 Seres Therapeutics completes enrolment in its phase III ECOSPOR III trial in Clostridium difficile infections (Recurrent) in USA, Canada (PO)
  • 31 Mar 2020 Seres Therapeutics plans to initiate an expanded access program in ongoing phase III ECOSPOR III trial in Clostridium difficile infections (Recurrent) in USA and Canada
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top